EPS for AngioDynamics, Inc. (ANGO) Expected At $0.20

March 16, 2018 - By Hazel Jackson

 EPS for AngioDynamics, Inc. (ANGO) Expected At $0.20
Investors sentiment decreased to 1.17 in Q3 2017. Its down 1.32, from 2.49 in 2017Q2. It worsened, as 13 investors sold AngioDynamics, Inc. shares while 52 reduced holdings. 24 funds opened positions while 52 raised stakes. 33.36 million shares or 0.00% more from 33.36 million shares in 2017Q2 were reported.
Great West Life Assurance Can holds 48,226 shares or 0% of its portfolio. Jpmorgan Chase Co has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 104,861 shares. Comerica Savings Bank holds 38,553 shares. Citadel Ltd Liability Com, Illinois-based fund reported 88,237 shares. Moreover, Ny State Teachers Retirement Systems has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 16,986 shares. 42,625 were reported by Cornercap Inv Counsel. Swiss Comml Bank holds 61,000 shares. Geode Cap Mgmt Ltd Co accumulated 0% or 395,969 shares. Bessemer Group Inc reported 0% stake. National Bank Of Montreal Can, Ontario – Canada-based fund reported 187,634 shares. Dimensional Fund Advsrs Limited Partnership invested in 3.09M shares or 0.02% of the stock. 10,998 were accumulated by Ubs Asset Management Americas. New York State Common Retirement Fund has 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO). Bowling Management Ltd Limited Liability Company invested in 49,090 shares or 0.13% of the stock. Rothschild Asset Mngmt holds 118,312 shares.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.20 EPS on March, 29 before the open.They anticipate $0.01 EPS change or 5.26 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.35M giving it 21.09 P/E if the $0.20 EPS is correct. After having $0.16 EPS previously, AngioDynamics, Inc.’s analysts see 25.00 % EPS growth. The stock increased 0.36% or $0.06 during the last trading session, reaching $16.87. About 174,305 shares traded. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since March 16, 2017 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 8 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. AngioDynamics had 20 analyst reports since July 24, 2015 according to SRatingsIntel. The rating was maintained by KeyBanc Capital Markets on Thursday, August 24 with “Hold”. The company was maintained on Wednesday, July 19 by Barclays Capital. The firm has “Hold” rating by Canaccord Genuity given on Tuesday, July 18. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Hold” rating by Canaccord Genuity on Sunday, October 8. The firm has “Overweight” rating given on Friday, July 24 by KeyBanc Capital Markets. On Thursday, January 4 the stock rating was maintained by Canaccord Genuity with “Hold”. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Buy” rating given on Friday, November 4 by Cantor Fitzgerald. The firm has “Hold” rating given on Friday, January 5 by Craig Hallum. On Monday, September 4 the stock rating was maintained by Canaccord Genuity with “Hold”. The firm earned “Neutral” rating on Wednesday, September 23 by Sidoti.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $619.90 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It currently has negative earnings. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

More recent AngioDynamics, Inc. (NASDAQ:ANGO) news were published by: Businesswire.com which released: “AngioDynamics to Report Fiscal 2018 Third Quarter Financial Results on March …” on February 27, 2018. Also Law360.com published the news titled: “Bankrupt Laser Co. Hid Assets To Duck Court Judgments: Suit” on March 16, 2018. Businesswire.com‘s news article titled: “AngioDynamics to Present at the Needham 17” with publication date: March 15, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.